Eventide Asset Management - TRILLIUM THERAPEUTICS INC ownership

TRILLIUM THERAPEUTICS INC's ticker is and the CUSIP is 89620X506. A total of 130 filers reported holding TRILLIUM THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.56 and the average weighting 0.3%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of TRILLIUM THERAPEUTICS INC
ValueSharesWeighting
Q3 2021$91,793,000
-0.5%
5,227,376
-45.0%
1.21%
-2.3%
Q2 2021$92,247,000
+12.1%
9,510,000
+24.2%
1.24%
+1.6%
Q1 2021$82,258,000
+17.0%
7,659,000
+60.2%
1.22%
+13.0%
Q4 2020$70,335,000
+54.8%
4,781,448
+49.6%
1.08%
+21.4%
Q3 2020$45,429,000
+120.5%
3,197,008
+25.5%
0.89%
+98.4%
Q2 2020$20,605,0002,547,0000.45%
Other shareholders
TRILLIUM THERAPEUTICS INC shareholders Q1 2021
NameSharesValueWeighting ↓
Anson Funds Management LP 174,174$298,0000.17%
Matrix Capital Management Company, LP 2,288,560$3,913,0000.13%
Samsara BioCapital, LLC 71,619$122,0000.12%
NEA Management Company, LLC 1,250,000$2,138,0000.08%
Tekla Capital Management LLC 446,099$763,0000.03%
PLATINUM INVESTMENT MANAGEMENT LTD 175,339$306,0000.01%
Artal Group S.A. 150,000$257,0000.01%
Baker Brothers Advisors 505,262$864,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 20,044$34,0000.01%
OXFORD ASSET MANAGEMENT LLP 57,055$98,0000.00%
View complete list of TRILLIUM THERAPEUTICS INC shareholders